We are live on ! Find out more
COCP icon

Cocrystal Pharma
COCP

22 hedge funds and large institutions have $4.85M invested in Cocrystal Pharma in 2018 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

15,509% more capital inflows, than outflows

Capital inflows: $3.55M | Capital outflows: $22.7K

1,000% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 1

69% more funds holding

Funds holding: 13 → 22 (+9)

3.68% more ownership

Funds ownership: 0.75% → 4.43% (+3.7%)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
22
Holders Change
+9
Holders Change %
+69.23%
% of All Funds
0.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
1
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Wasatch Advisors
Wasatch Advisors
Utah
+$1.56M
2
Millennium Management
Millennium Management
New York
+$1.27M
3
KeyBank National Association
KeyBank National Association
Ohio
+$241K
4
Goldman Sachs
Goldman Sachs
New York
+$128K
5
BlackRock
BlackRock
New York
+$99K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$15K
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$6.16K
3
Bank of America
Bank of America
North Carolina
-$1.56K

COCP Hedge Fund Activity: Q2 2018 in Review

22 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in Cocrystal Pharma (COCP) for Q2 2018, worth a combined $4.85M — up 343% from $1.1M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new COCP positions and 1 closed out — a net gain of 10 holders — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Wasatch Advisors, opening a new position worth an estimated $1.56M. The largest seller was UBS Group, exiting entirely with an estimated $15K sold.

  • 22 institutional investors held Cocrystal Pharma (COCP) as of Q2 2018, up from 13 in Q1 2018.
  • Funds reported $4.85M of Cocrystal Pharma stock for Q2 2018, up 343% quarter-over-quarter.
  • 11 funds opened new Cocrystal Pharma positions in Q2 2018 and 1 closed out, a net change of +10 holders.
  • The largest Cocrystal Pharma buyer in Q2 2018 was Wasatch Advisors, an estimated $1.56M added.
  • The largest Cocrystal Pharma seller in Q2 2018 was UBS Group, an estimated $15K sold.

Based on aggregated 13F filings for Q2 2018.